Two Sigma Securities, LLC Gilead Sciences, Inc. Call Options Transaction History

Two Sigma Securities, LLC

$10.3 Billion
Q1 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $3.99 Million - $4.86 Million	-55,700 Reduced 60.35%	36,600 $2.68 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $2.12 Million - $2.41 Million	29,000 Added 45.81%	92,300 $7.48 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $739,400 - $806,700	-10,000 Reduced 13.64%	63,300 $4.74 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $2.74 Million - $3.13 Million	36,100 Added 97.04%	73,300 $5.65 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $1.57 Million - $1.79 Million	20,300 Added 120.12%	37,200 $3.09 Million

Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $3.38 Million - $4.86 Million	-54,300 Reduced 76.26%	16,900 $1.45 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $8.97 Million - $10.2 Million	-150,700 Reduced 67.91%	71,200 $4.39 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $7.58 Million - $8.54 Million	131,300 Added 144.92%	221,900 $13.7 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $4.67 Million - $5.85 Million	80,600 Added 806.0%	90,600 $5.39 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $3.04 Million - $3.45 Million	-46,900 Reduced 82.43%	10,000 $726,000
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $1.43 Million - $1.54 Million	21,100 Added 58.94%	56,900 $3.97 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $1.61 Million - $1.75 Million	25,300 Added 240.95%	35,800 $2.47 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $3.39 Million - $3.87 Million	-56,500 Reduced 84.33%	10,500 $679,000
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $2.94 Million - $3.35 Million	51,900 Added 343.71%	67,000 $3.9 Million
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $149,040 - $187,392	-2,400 Reduced 13.71%	15,100 $954,000
Q2 2020 Sep 10, 2020	SELL	$72.34 - $84.0 $1.09 Million - $1.27 Million	-15,100 Reduced 46.32%	17,500 $1.35 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $18.9 Million - $24.2 Million	-302,100 Reduced 90.26%	32,600 $2.44 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $20.6 Million - $22.7 Million	334,700 New	334,700 $21.7 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $6.3 Million - $6.96 Million	-100,800 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $3.84 Million - $4.3 Million	62,000 Added 159.79%	100,800 $6.81 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $4.09 Million - $4.58 Million	-65,400 Reduced 62.76%	38,800 $2.52 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $3.23 Million - $4.21 Million	-53,300 Reduced 33.84%	104,200 $6.52 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $7.36 Million - $8.15 Million	-103,300 Reduced 39.61%	157,500 $12.2 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $5.25 Million - $6.12 Million	-80,900 Reduced 23.68%	260,800 $18.5 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $21.8 Million - $26.6 Million	299,200 Added 704.0%	341,700 $25.8 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $3.02 Million - $3.55 Million	42,500	42,500 $3.05 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

Black Rock Inc. New York, NY

123M
Shares

$8.38 Billion
0.21% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$7.85 Billion
0.17% of portfolio
Capital World Investors Los Angeles, CA

84.5M
Shares

$5.78 Billion
1.06% of portfolio
Capital Research Global Investors Los Angeles, CA

61.2M
Shares

$4.19 Billion
1.05% of portfolio
State Street Corp Boston, MA

57.7M
Shares

$3.95 Billion
0.19% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.

Account